Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

91 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Patients transitioning from non-pegylated to pegylated interferon beta-1a have a low risk of new flu-like symptoms: ALLOW phase 3b trial results.
Naismith RT, Hendin B, Wray S, Huang D, Gaudenzi F, Dong Q, Sperling B, Mann M, Werneburg B. Naismith RT, et al. Among authors: sperling b. Mult Scler J Exp Transl Clin. 2019 Jan 30;5(1):2055217318822148. doi: 10.1177/2055217318822148. eCollection 2019 Jan-Mar. Mult Scler J Exp Transl Clin. 2019. PMID: 30729026 Free PMC article.
The MSOAC approach to developing performance outcomes to measure and monitor multiple sclerosis disability.
LaRocca NG, Hudson LD, Rudick R, Amtmann D, Balcer L, Benedict R, Bermel R, Chang I, Chiaravalloti ND, Chin P, Cohen JA, Cutter GR, Davis MD, DeLuca J, Feys P, Francis G, Goldman MD, Hartley E, Kapoor R, Lublin F, Lundstrom G, Matthews PM, Mayo N, Meibach R, Miller DM, Motl RW, Mowry EM, Naismith R, Neville J, Panagoulias J, Panzara M, Phillips G, Robbins A, Sidovar MF, Smith KE, Sperling B, Uitdehaag BM, Weaver J; Multiple Sclerosis Outcome Assessments Consortium (MSOAC). LaRocca NG, et al. Among authors: sperling b. Mult Scler. 2018 Oct;24(11):1469-1484. doi: 10.1177/1352458517723718. Epub 2017 Aug 11. Mult Scler. 2018. PMID: 28799444 Free PMC article. Review.
Multiple sclerosis patients treated with intramuscular IFN-β-1a autoinjector in a real-world setting: prospective evaluation of treatment persistence, adherence, quality of life and satisfaction.
Hupperts R, Becker V, Friedrich J, Gobbi C, Salgado AV, Sperling B, You X. Hupperts R, et al. Among authors: sperling b. Expert Opin Drug Deliv. 2015 Jan;12(1):15-25. doi: 10.1517/17425247.2015.989209. Epub 2014 Nov 28. Expert Opin Drug Deliv. 2015. PMID: 25430947 Clinical Trial.
Long-term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
Gryglas-Dworak A, Schim J, Ettrup A, Boserup LP, Josiassen MK, Ranc K, Sperling B, Ashina M. Gryglas-Dworak A, et al. Among authors: sperling b. Headache. 2025 Jan;65(1):101-112. doi: 10.1111/head.14862. Epub 2024 Nov 5. Headache. 2025. PMID: 39501727 Free PMC article. Clinical Trial.
91 results